Heinz Ludwig

Q: What Schools Are Affiliated With Heinz Ludwig

Heinz Ludwig is affiliated with the following schools: University of Innsbruck, Medical University of Vienna, University of Cologne, Semmelweis University, National and Kapodistrian University of Athens, University of Turin, University of Salamanca, Masaryk University, University of Vienna, Technical University of Berlin

Heinz Ludwig's AcademicInfluence.com Rankings

Heinz Ludwig

Physics

#5412

World Rank

#7243

Historical Rank

physics Degrees

Download Badge

Physics

Why Is Heinz Ludwig Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Heinz Ludwig's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group (2003) (2143)
International uniform response criteria for multiple myeloma (2006) (2014)
International staging system for multiple myeloma. (2005) (1929)
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. (2009) (1610)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. (2016) (1536)
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. (2011) (862)
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. (2015) (809)
The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. (2004) (783)
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma (2008) (764)
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders (2009) (718)
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. (2014) (666)
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. (2016) (662)
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management (2010) (660)
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. (2015) (532)
International uniform response criteria for multiple myeloma (2006) (519)
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. (2003) (445)
Erythropoietin treatment of anemia associated with multiple myeloma. (1990) (440)
The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer (1993) (428)
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. (2011) (406)
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (378)
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. (2010) (365)
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). (2011) (328)
Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. (1998) (318)
Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. (2000) (314)
Thalidomide for treatment of multiple myeloma: 10 years later. (2008) (296)
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. (2011) (295)
Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. (2015) (293)
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group (2013) (289)
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications (2015) (283)
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group (2018) (279)
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (279)
The challenge of biosimilars. (2008) (277)
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. (2016) (277)
Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). (1998) (272)
Pathogenesis and treatment of renal failure in multiple myeloma (2008) (269)
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. (2017) (259)
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study (2016) (235)
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. (2009) (220)
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. (2009) (217)
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. (2019) (213)
Symptomatology of anemia. (2001) (211)
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) (2014) (211)
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. (2010) (204)
Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes (2010) (204)
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) (2009) (202)
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia (2012) (198)
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. (2008) (198)
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. (2018) (195)
Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. (2008) (195)
IMWG consensus on maintenance therapy in multiple myeloma. (2012) (191)
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies (2005) (191)
Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. (1996) (191)
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma (2014) (191)
Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group (2016) (189)
Anemia in cancer patients. (1998) (185)
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. (2018) (185)
International Myeloma Working Group recommendations for global myeloma care (2014) (183)
Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. (2000) (180)
Cancer-Related Anemia: Pathogenesis, Prevalence and Treatment (2005) (179)
Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. (2000) (170)
Prediction of response to erythropoietin treatment in chronic anemia of cancer [see comments] (1994) (165)
Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin (1994) (164)
Lenalidomide downregulates the cell survival factor, interferon regulatory factor‐4, providing a potential mechanistic link for predicting response (2011) (157)
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel (2018) (152)
Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. (1997) (146)
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 stud (2020) (144)
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation (2009) (143)
Survival and years of life lost in different age cohorts of patients with multiple myeloma. (2010) (142)
Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. (1995) (139)
Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. (2009) (137)
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multip (2015) (134)
Anemia management in oncology and hematology. (2009) (134)
Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia (2013) (130)
Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. (2010) (128)
Interleukin-6 is a prognostic factor in multiple myeloma [letter] [see comments] (1991) (128)
Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma (2007) (127)
The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network (2014) (120)
Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. (2012) (119)
Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. (2009) (117)
Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion (2007) (115)
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement (2011) (114)
Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study (2007) (112)
High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone (2013) (112)
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma (2014) (112)
Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients (2012) (111)
Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY (2006) (108)
Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. (1996) (105)
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives (2017) (104)
A practical update on the use of bortezomib in the management of multiple myeloma. (2006) (104)
Prediction of response to erythropoietin treatment in chronic anemia of cancer. (1994) (103)
Interleukin-6 is a prognostic factor in multiple myeloma. (1991) (103)
The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. (1995) (101)
A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. (1985) (100)
Interferon-α Stimulates the Hypothalamic- Pituitary-Adrenal Axis in vivo and in vitro (1993) (100)
LONG-TERM INTERFERON THERAPY FOR THROMBOCYTOSIS IN MYELOPROLIFERATIVE DISEASES (1989) (98)
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN) (2020) (98)
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS) (2016) (98)
Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. (1993) (96)
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines† (2018) (95)
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective (2010) (94)
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial (2019) (92)
European perspective on multiple myeloma treatment strategies in 2014. (2014) (92)
Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. (1995) (91)
Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. (2014) (91)
Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen. (1997) (90)
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) (2020) (89)
Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. (1991) (85)
Prognostic relevance of cellular morphology in multiple myeloma. (1984) (82)
Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. (2013) (81)
Quantitative MRI in CADASIL (1999) (81)
Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy (1995) (80)
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. (2021) (78)
Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma (2010) (77)
European perspective on multiple myeloma treatment strategies: update following recent congresses. (2012) (77)
Radiography and bone scintigraphy in multiple myeloma: a comparative analysis. (1982) (76)
Treatment of relapsed and refractory multiple myeloma in the era of novel agents. (2011) (76)
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) (2018) (75)
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when (2018) (75)
Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance (2000) (73)
MAGNETIC RESONANCE IMAGING OF THE SPINE IN MULTIPLE MYELOMA (1987) (72)
Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis (2011) (71)
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network (2020) (70)
Second primary malignancies in multiple myeloma: an overview and IMWG consensus. (2016) (69)
Reversal of multi‐drug resistance in human KB cell lines by structural analogs of verapamil (1990) (68)
MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents (2020) (63)
Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis--a critical review. (2014) (63)
Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection (1996) (63)
Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study) (2016) (61)
Anemia in multiple myeloma. (2004) (61)
Magnetic resonance imaging of the lower vertebral column in patients with multiple myeloma. (1988) (61)
Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study. (2009) (61)
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. (2016) (61)
Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT) (2013) (60)
Cancer-Related Anemia: Biological Findings, Clinical Implications and Impact on Quality of Life (2005) (60)
Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial). (2016) (60)
Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis (2018) (59)
Independent Risk Factors for Anemia in Cancer Patients Receiving Chemotherapy: Results from the European Cancer Anaemia Survey (2006) (59)
Overexpression of G protein‐coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma (2012) (59)
Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma (2006) (58)
Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA) (2018) (58)
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study (2016) (58)
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network (2017) (57)
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study (2017) (57)
Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis. (2019) (56)
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013) (56)
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study (2017) (56)
Interferon‐alpha‐induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis (1990) (55)
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. (2018) (55)
Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment (2017) (53)
Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma (2001) (52)
Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations. (2002) (52)
Interferon-alpha stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro. (1993) (51)
Multiple Myeloma Treatment in Real‐world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study (2018) (51)
Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma. (1999) (50)
Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. (2013) (49)
Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR (2016) (49)
Anemia of cancer patients: patient selection and patient stratification for epoetin treatment. (1998) (49)
Psychosocial QOL is an independent predictor of overall survival in newly diagnosed patients with multiple myeloma (2008) (49)
Deletion of 13 q 14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization (2000) (47)
Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent (2005) (46)
Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM) (2012) (46)
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma (2017) (46)
Shortened platelet half-life in multiple myeloma. (1986) (45)
Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial. (1986) (45)
Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment (2016) (44)
Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment (2020) (43)
A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial (2018) (43)
Second primary malignancies in multiple myeloma: an overview and IMWG consensus. (2018) (42)
Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. (2012) (41)
Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. (2009) (41)
Supportive care in multiple myeloma. (2007) (41)
Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial) (2016) (39)
Updated Survival Analysis from the CLL11 Study: Obinutuzumab Versus Rituximab in Chemoimmunotherapy-Treated Patients with Chronic Lymphocytic Leukemia (2015) (39)
Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. (2019) (39)
Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma (2015) (39)
Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. (2011) (39)
Novel Therapeutic Agents for the Management of Patients with Multiple Myeloma and Renal Impairment (2012) (39)
Absence of clonal chromosomal relationship between concomitant B-CLL and multiple myeloma – a report on two cases (2001) (38)
Management of Multiple Myeloma with Bortezomib: Experts Review the Data and Debate the Issues (2007) (37)
Erratum: International uniform response criteria for multiple myeloma (Leukemia (2006) vol. 20 (1467-1473) 10.1038/sj.leu.2404284) (2006) (37)
Patient preferences for interferon alfa in multiple myeloma. (1997) (37)
Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma (2008) (37)
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension (2019) (37)
Randomised study using IFN-a versus IFN-a plus coumarin and cimetidine for treatment of advanced renal cell cancer (1995) (37)
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma (2016) (36)
Epidemiologic and age-dependent data on multiple myeloma in Austria. (1982) (35)
Interferon in essential thrombocythaemia (1991) (35)
for treatment of advanced (1990) (34)
Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma (1993) (34)
Thalidomide-Dexamethasone Versus Melphalan-Prednisolone as First Line Treatment in Elderly Patients with Multiple Myeloma: An Interim Analysis. (2005) (34)
Epoetin in cancer-related anaemia. (1999) (34)
Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866) (2015) (33)
Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. (2012) (33)
Insights on Multiple Myeloma Treatment Strategies (2018) (33)
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma (2017) (33)
Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy (2014) (33)
The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. (2016) (32)
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network (2021) (32)
Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial) (2016) (32)
Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): Results from the phase III study ENDEAVOR. (2015) (32)
How I manage the toxicities of myeloma drugs. (2017) (31)
Erythropoietins should be used according to guidelines. (2008) (31)
A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia (2014) (31)
Anemia of hematologic malignancies: what are the treatment options? (2002) (31)
International uniform response criteria for multiple myeloma (2007) (30)
Immunohistochemical evaluation of cathepsin D expression in colorectal cancer. (1997) (30)
Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study. (1997) (30)
Long-term alpha-interferon therapy in myelodysplastic syndromes. (1990) (29)
Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study) (2016) (28)
Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results. (1991) (28)
Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. (2019) (28)
Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up (2015) (27)
EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma (2017) (27)
Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19+ cells in patients with myeloma and monoclonal gammopathy of undetermined significance (2002) (27)
Management of complications in multiple myeloma. (2009) (27)
Patterns of somatic mutations in VH genes reveal pathways of clonal transformation from MGUS to multiple myeloma. (2003) (27)
Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro. (2014) (27)
Genetic aspects of susceptibility to multiple myeloma. (1982) (26)
Chromosome 7 deletions are associated with unfavorable prognosis in myelofibrosis with myeloid metaplasia. (2005) (26)
Immunophenotypic characterization of myelomonocytic cells in patients with myelodysplastic syndrome (1993) (26)
Predicting the Hematopoietic Response to Recombinant Human Erythropoietin (Epoetin Alfa) in the Treatment of the Anemia of Cancer (1999) (26)
Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup (2015) (25)
LEADING ARTICLE International uniform response criteria for multiple myeloma (2006) (25)
Absence of p53 deletions in bone marrow plasma cells of patients with monoclonal gammopathy of undedetermined significance (1998) (25)
Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim. (2011) (24)
Hematological emergencies. (2007) (24)
Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma (2019) (24)
Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders (2004) (24)
Age and hemoglobin level emerge as most important clinical prognostic parameters in patients with osteomyelofibrosis: introduction of a simplified prognostic score (2006) (23)
Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma (2015) (23)
Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study). (2017) (23)
Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus ≥10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial (2009) (23)
[Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses]. (1985) (23)
Treatment with recombinant interferon-alpha-2C: multiple myeloma and thrombocythaemia in myeloproliferative diseases. (1985) (23)
Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study (2015) (23)
Multiple myeloma: an update on biology and treatment. (1999) (23)
Advances in molecular biology diagnostic and treatment of B-cell malignancies: Advances in biology and treatment of multiple myeloma (2005) (22)
Exome sequencing in tracking clonal evolution in multiple myeloma following therapy (2013) (22)
Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma (2017) (22)
Evaluating the clonal hierarchy in light-chain multiple myeloma: implications against the myeloma stem cell hypothesis (2011) (21)
Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma. (2007) (21)
5q- chromosome in acute leukemia with lymphoid morphology and expression of myeloid membrane determinants. (1985) (20)
Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes (2017) (20)
Phase II results with recombinant interferons: renal cell carcinoma and malignant melanoma. (1985) (20)
ASHO position paper on Biosimilars (2009) (20)
Fixed duration vs continuous therapy in multiple myeloma. (2017) (20)
Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial (2015) (19)
Seborrhoeic keratoses in patients with internal malignancies: a case–control study with prospective accrual of patients (2009) (19)
Erythropoietin treatment of chronic anaemia of cancer. (1993) (19)
Recovery of Renal Impairment by Bortezomib-Doxorubicin-Dexamethasone (BDD) in Multiple Myeloma (MM) Patients with Acute Renal Failure. Results from an Ongoing Phase II Study. (2007) (19)
Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment and Thalidomide-Interferon vs. Interferon Maintenance Therapy in Elderly Patients with Multiple Myeloma. (2007) (19)
[Interferon in the treatment of multiple myeloma]. (1985) (19)
Heterogeneity of serological responses in paucibacillary leprosy--differential responses to protein and carbohydrate antigens and correlation with clinical parameters. (1990) (18)
Molecular mechanisms, current management and next generation therapy in myeloma bone disease (2018) (18)
Iron Metabolism and Iron Supplementation in Anemia of Cancer (2006) (18)
Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study. (1999) (18)
Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial (2017) (18)
Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia (2006) (18)
Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study (2017) (18)
Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma (2016) (18)
A paraneoplastic syndrome mimicking extrauterine pregnancy. (2002) (18)
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. (2022) (17)
Abstract 3847: The anti-hepcidin Spiegelmer® Lexaptepid Pegol (NOX-H94) as treatment of anemia of chronic disease in patients with multiple myeloma, low grade lymphoma, and CLL: A phase II pilot study (2014) (17)
Comparison of Technetium-99m-MIBI imaging with MRI for detection of spine involvement in patients with multiple myeloma (2003) (17)
Thalidomide treatment in multiple myeloma. (2002) (17)
Final Analysis of Overall Survival from the First Trial (2016) (17)
Erratum: Myeloma management guidelines: A consensus report from the scientific advisors of the international myeloma foundation (The Hematology Journal (2003) vol, 4 (379-398) 10.1038/sj.thj.6200312) (2004) (17)
rHuEPO and treatment outcomes: the preclinical experience. (2004) (16)
LBA28CARFILZOMIB (K) VS LOW-DOSE CORTICOSTEROIDS AND OPTIONAL CYCLOPHOSPHAMIDE (CY) IN PATIENTS (PTS) WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 3 STUDY (FOCUS) (2014) (16)
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population (2020) (16)
Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network (2019) (16)
Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma (2010) (16)
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma (2010) (16)
Chromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the International Staging System (2007) (16)
In vivo tracing of indium-111 oxine-labeled human peripheral blood mononuclear cells in patients with lymphatic malignancies. (1989) (16)
Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma. (2014) (16)
Clinical immunology and allergology : proceedings of the symposia at the XIth Congress of the European Academy of Allergology and Clinical Immunology held in Vienna, Austria, 6-10 October 1980 (1981) (16)
Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥10 g/dL: an exploratory analysis of a phase 3 trial (2012) (15)
Randomised study using IFN-alpha versus IFN-alpha plus coumarin and cimetidine for treatment of advanced renal cell cancer. (1995) (15)
Individualized chemotherapy in multiple myeloma by cytostatic drug sensitivity testing of colony-forming stem cells. (1981) (15)
Neoadjuvant chemotherapy (MVAC) in locally invasive bladder cancer. (1996) (15)
Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments. (2011) (15)
Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma (2019) (15)
Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease (2018) (14)
The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study: a global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines (2008) (14)
Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. (2020) (13)
Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: An interim analysis (2005) (13)
Phagocytic plasma cells in a patient with multiple myeloma. (1980) (13)
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma (2021) (13)
Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study (2020) (13)
Ferritin as prognostic marker in multiple myeloma patients undergoing autologous transplantation (2014) (13)
Placebo-Controlled Trial of Medroxy – progesterone Acetate in Gastrointestinal Malignancies and Cachexia (1996) (13)
Induction of indoleamine-2,3 dioxygenase in bone marrow stromal cells inhibits myeloma cell growth (2012) (12)
Neurological function during long-term therapy with recombinant interferon alpha. (1999) (12)
The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy (2017) (12)
The anti‐mitotic agents PTC‐028 and PTC596 display potent activity in pre‐clinical models of multiple myeloma but challenge the role of BMI‐1 as an essential tumour gene (2020) (12)
The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy (2007) (12)
Combined alpha-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: a prospective randomized trial. (1989) (12)
Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients (2013) (11)
Acute encephalopathy associated with continuous vincristine sulfate combination therapy: case report (2004) (11)
Corrections to "Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines". (2018) (11)
Acute bilateral renal vein thrombosis complicating Netherton syndrome (1998) (11)
Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data (2019) (11)
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde (2021) (11)
Continuing medical education: a must for every medical oncologist. (2003) (11)
Modeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient-related variables: results from the Anemia Cancer Treatment (ACT) study. (2009) (11)
Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1 (2018) (11)
Immunological findings in patients with myelodysplastic syndrome. (1994) (10)
Covid‐19 vaccination in patients with multiple myeloma: Focus on immune response (2021) (10)
1120 POSTER Evaluation of the association between hemoglobin (Hb) events and safety outcomes in cancer patients (pts) with chemotherapy-induced anemia (CIA): an integrated analysis of patient-level data from 6 randomized, placebo-controlled trials (RCTs) of darbepoetin alfa (DA) (2007) (10)
Health Related Quality of Life Results from the Open-Label, Randomized, Phase III Endeavor Trial Evaluating Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (2016) (10)
Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study. (2019) (10)
Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy? (2012) (10)
PLASMA CELL LEUKEMIA : Consensus Statement on Diagnostic Requirements , Response Criteria , and Treatment Recommendations by the International Myeloma Working Group ( IMWG ) (2014) (10)
Suboptimal hemoglobin levels: do they impact patients and their therapy? Audience responses. (2000) (10)
Update on the rational use of 90Y-ibritumomab tiuxetan in the treatment of follicular lymphoma (2009) (10)
Effect of interferon alpha-2a on hormone receptor status in patients with advanced breast cancer. (1999) (10)
Weekly low dose doxorubicin monotherapy in metastatic breast cancer resistant to previous hormonal and cytostatic treatment (2005) (10)
Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated “same-day” (< 24 h), “per-guidelines” (24–72 h), and “late” (> 72 h): findings from the MONITOR-GCSF study (2018) (10)
"Benign" monoclonal IgE gammopathy. (1980) (10)
Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866) (2015) (9)
Additional Lesions Detected in Therapeutic Scans with 177Lu-DOTATATE Reflect Higher Affinity of 177Lu-DOTATATE for Somatostatin Receptors (2011) (9)
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. (2017) (9)
Short Survival, Despite Promising Response Rates, after Bortezomib Treatment of Multiple Myeloma Patients with a 13q-Deletion. (2005) (9)
Publisher Correction: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group (2018) (9)
Bortezomib-Doxorubicin-Dexamethasone (BDD) in Patients with Acute Light Chain Induced Renal Failure (ARF) in Multiple Myeloma (MM). Final Results of a Phase II Study. (2009) (9)
Bortezomib(Velcade®)-Thalidomide-Dexamethasone (VTD) Is Superior to Thalidomide-Dexamethasone (TD) In Patients with Multiple Myeloma (MM) Progressing or Relapsing After Autologous Transplantation (2010) (8)
Phase I study of recombinant human interferon alpha-2C in patients with chemotherapy-refractory malignancies. (1985) (8)
High Expression of the Thalidomide-Binding Protein Cereblon (CRBN) Is Associated with Improved Clinical Response in Patients with Multiple Myeloma Treated with Lenalidomide and Dexamethasone (2011) (8)
"Benign" monoclonal IgE gammopathy. (1981) (8)
IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide‐dexamethasone therapy in multiple myeloma (2017) (8)
Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial. (2009) (8)
Surface morphology of normal and chronic lymphocytic leukaemia lymphocytes. (1976) (8)
Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between GDP/Capita, Access to Cancer Drugs, Patient Visits to the IMF Website and Mortality-to-Incidence Ratio as Proxy for Survival (2019) (8)
Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391). (2015) (8)
MyelomA Genetics International Consortium (2012) (8)
Usage of HLC-Ratio, FLC-Ratio, Ife, PBMC Infiltration and Isotype Suppression At Best Response Reveals Isotype Suppression As Most Powerful Parameter for Identification of Multiple Myeloma Patients with Long Survival (2012) (8)
Carfilzomib–dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study (2018) (8)
Intravenous Ferric Carboxymaltose As Sole Anemia Therapy In Patients With Lymphoid Malignancies, Chemotherapy-Induced Anemia and Functional Iron Deficiency (2013) (8)
Supportive therapy in multiple myeloma. (2011) (7)
Trisomy 13 is associated with poor prognosis in idiopathic myelofibrosis with myeloid metaplasia. (1999) (7)
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. (2018) (7)
A plasma clot culture system for growing and antiproliferative drug sensitivity testing of myeloma stem cells. (1984) (7)
Serum Heavy/Light Chain and Free Light Chain Measurements Provide Prognostic Information, Allow Creation of a Prognostic Model and Identify Clonal Changes (clonal tiding) Through the Course of Multiple Myeloma (MM) (2011) (7)
Impaired conversion of exogenous arachidonic acid by platelets to thromboxane B2 and correction of that deficiency by interferon-alpha. (1990) (7)
Phase II evaluation of 5-fluorouracil, folinic acid and cisplatin in advanced-stage colorectal adenocarcinoma. (1989) (7)
Defects of leukocyte locomotion in multiple myeloma. (1982) (7)
Deep Vein Thrombosis in Myeloma: Estimate of Prevelance and Recommendations for Therapy Based upon a Survey of Members of the International Myeloma Working Group (IMWG). (2006) (7)
[Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)]. (2012) (6)
Results of a New Drug Combination (VP-16 — Ifosfamide — Mitoxantrone — Bleomycin/VIM-BLEO) in Advanced Non-Hodgkin’s Lymphomas (1987) (6)
Anaemia in elderly patients with cancer: Focus on chemotherapy-induced anaemia (2012) (6)
Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer® Olaptesed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma (2014) (6)
Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study (2014) (6)
Continuous prednisolone versus conventional prednisolone with VMCP–interferon‐α2b as first‐line chemotherapy in elderly patients with multiple myeloma (2005) (6)
Mitoxantrone-induced discoloration of the nails. (1989) (6)
ESAs not the culprit: More studies required (2008) (6)
Anti-CXCL12/SDF-1 Spiegelmer® Nox-A12 Alone and In Combination With Bortezomib and Dexamethasone In Patients With Relapsed Multiple Myeloma: Results From A Phase IIa Study (2013) (6)
Prevalence of comorbidity in cancer patients scheduled for systemic anticancer treatment in Austria (2019) (6)
Serum ferritin and beta 2-microglobulin in patients with multiple myeloma. (1983) (6)
The Ratio of Monoclonal to Polyclonal Immunoglobulins Assessed with the Hevylite Test Predicts Prognosis, Is Superior for Monitoring the Course of the Disease and Allows Detection of Monoclonal Immunoglobulin In Patients with Normal or Subnormal Involved Immunoglobulin Isotype (2010) (6)
Reversal of acute renal impairment bybortezomib-doxorubicin-dexamathasone in multiple myeloma.Results from an phase II study (2009) (6)
Should-alpha-interferon be included as standard treatment in multiple myeloma? (1998) (6)
Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma (2010) (6)
Treatment with Bendamustine-Bortezomib-Dexamethasone (BBD) in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated (2012) (5)
Maximal androgen blockade in combination with methotrexate for treatment of metastatic prostate cancer (2005) (5)
The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma (2014) (5)
Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis (2013) (5)
Experiences with continuous intraarterial administration of recombinant interferon alpha-2C (rIFN-alpha 2) for treatment of patients with advanced transitional cell bladder cancer. (1988) (5)
Ultrastructural studies of myeloma cells: Observations concerning the Golgi apparatus and intermediate‐size filaments (1983) (5)
Cytogenetic patterns in multiple myeloma after a phase of preceding MGUS (2007) (5)
Outcomes of patients with t(11;14) multiple myeloma: An International Myeloma Working Group (IMWG) multicenter study. (2019) (5)
Increase of bone marrow cellularity during erythropoietin treatment in myeloma. (1995) (5)
Daratumumab: a game changer in myeloma therapy. (2020) (5)
LENALIDOMIDE plus LOW-DOSE DEXAMETHASONE (RD) VS. MELPHALAN-PREDNISONE-THALIDOMIDE (MPT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS (PTS): THE FIRST TRIAL (2014) (5)
Recent therapeutic advances in hematological malignancies: dealing with treatment-related complications. (2008) (5)
Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma (2021) (5)
Cereblon expression in multiple myeloma: not ready for prime time – Response to Lodé et al (2013) (5)
Bortezomib-Doxorubicin-Dexamethasone (BDD) for Reversal ofAcute Light Chain Induced Renal Failure (ARF) in MultipleMyeloma (MM). Results from a Phase II Study (2008) (5)
BMP-2: a culprit for anemia in myeloma. (2010) (5)
Combined Interferon-Polychemotherapy versus Polychemotherapy in Multiple Myeloma: A Phase-III Study (1987) (5)
Updated Overall Survival (OS) Analysis of the FIRST Study: Lenalidomide Plus Low-Dose Dexamethasone (Rd) Continuous vs Melphalan, Prednisone, and Thalidomide (MPT) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) (2015) (5)
Epoetin beta in oncology: examining the current evidence. (2006) (5)
Bortezomib-Bendamustine-Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM) Shows Marked Efficacy and Is Well Tolerated, but Assessment of PNP Symptoms Shows Significant Discrepancies Between Patients and Physicians (2011) (5)
Advances in biology and treatment of multiple myeloma. (2005) (5)
Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials (2020) (5)
Successful treatment of a patient with lymphocyte‐predominant Hodgkin’s lymphoma with yttrium‐90‐ibritumomab tiuxetan (2008) (5)
Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial (2016) (4)
[Erythropoietin treatment of tumor-associated anemia in patients with multiple myeloma]. (1990) (4)
Early‐onset thrombocytopenia during combination chemotherapy in testicular cancer is induced by vinblastine (1989) (4)
The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies (2017) (4)
Phase II study of bortezomib, thalidomide, and dexamethasone /-cyclophosphamide as induction therapy in previously untreatedmultiple myeloma (MM): safety and activity including evaluationof MRD (2010) (4)
101 Age- and comorbidity-specific evaluation of azacitidine treatment, response and overall survival in 184 patients in the Austrian Azacitidine Registry (2011) (4)
Supportive therapies in the management of myeloma. (2004) (4)
Phase II trial of recombinant interferon alpha-2C in metastatic renal cell carcinoma. (1987) (4)
The current landscape of multiple myeloma treatment. (2008) (4)
Multiple Myeloma Drivers of High Risk and Response to Stem Cell Transplantation Identified By Causal Machine Learning: Out-of-Cohort and Experimental Validation (2017) (4)
Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02) (2019) (4)
Navratil, Käser, Ober (2007) (4)
Threatening clots in MGUS and myeloma. (2010) (4)
European Society of Medical Oncology membership survey (2004) (4)
Management of Non-Hodgkin’s Lymphomas in Elderly Patients: Conclusions of the Second Intercity Meeting, 1987 (1990) (4)
Diagnosis, treatment, and use of intravenous iron for chemotherapy-induced anemia in Europe. (2011) (4)
Keynote comment: inequalities and shortcomings in European cancer care. (2006) (4)
FIRST study: Updated overall survival (OS) in stem cell transplant (SCT)-ineligible newly diagnosed multiple myeloma (NDMM) patients (pts) treated with continuous lenalidomide plus low-dose dexamethasone (Rd) vs melphalan, prednisone, and thalidomide (MPT). (2015) (4)
Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial (2018) (4)
Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone (KRd) vs Lenalidomide and Dexamethasone (Rd) in Patients (Pts) With Relapsed Multiple Myeloma (RMM) Based on Age: Secondary Analysis From the Phase 3 Study ASPIRE (NCT01080391) (2015) (4)
Effect of recombinant interferon-alpha2C on reticuloendothelial function in patients with thrombocytosis. (1990) (4)
A147 Thalidomide/Interferon Versus Interferon Maintenance After Thal/Dex Versus MP (2009) (3)
VAD protocol for treatment of advanced refractory multiple myeloma (1987) (3)
Reduced alpha diversity of the oral microbiome correlates with short progression‐free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib‐based therapy (AGMT MM 1, phase II trial) (2020) (3)
1104 POSTER Patient-level integrated analysis of data from 6 randomized, double-blind, placebo-controlled trials of darbepoetin alfa (DA) in patients (pts) with chemotherapy-induced anemia (CIA) (2007) (3)
The European Medicines Agency Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma (2017) (3)
Sequential high-dose methotrexate, 5-fluorouracil, and doxorubicin for treatment of advanced pancreatic cancer (2005) (3)
[The clinical picture of multiple myeloma]. (1986) (3)
The Effect of Hemoglobin (Hb) Level at ESA Initiation on Outcomes in Cancer Patients (pts) with Chemotherapy-Induced Anemia (CIA): A Patient-Based Meta-Analysis from 6 Randomized, Placebo-Controlled Trials (RCTs) of Darbepoetin alfa (DA). (2007) (3)
Multiple myeloma: new treatments gain momentum (2017) (3)
Compliance With Vaccination Recommendations Among Patients With Multiple Myeloma: A Real World Experience (2021) (3)
EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma (2018) (3)
Current Practice In Diagnosis and Treatment of Chemotherapy-Induced Anemia In Five European Countries – A Patient Record Study (2010) (3)
Dose Escalation of Ara-C May Improve Response Rates in a Subgroup of Chronic Myeloid Leukemia Patients with Poor Response to Interferon-α and Low-dose Ara-C (2001) (3)
TUMOUR‐PROMOTING COMPOUND (TPA) ENHANCES INTERFERON PRODUCTION IN CHRONIC LYMPHATIC LEUKAEMIA CELLS (1981) (3)
[Defects in the prostaglandin system. VIII. A pathologic thrombocyte population in myeloproliferative syndrome, which forms no thromboxane from exogenous arachidonic acid]. (1988) (3)
Carfilzomib and dexamethasone (Kd56) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Updated overall survival (OS), safety, and subgroup analysis of ENDEAVOR. (2018) (3)
Optimum cancer care--an unaffordable goal? (2004) (3)
100 Overall survival data of patients with MDS, AML and CMML from the Austrian Azacitidine Registry of 184 consecutive patients (2011) (3)
Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib in Relapsed/Refractory Multiple Myeloma. (2006) (3)
Physical, emotional and social pain communication by patients diagnosed and living with multiple myeloma. (2021) (3)
Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated Outside the Clinical Trial Setting Via an Early Access Program (EAP) in Europe: Second Interim Analysis of the 'Use Via Early Access to Ixazomib' (UVEA-IXA) Study (2020) (3)
Preclinical Validation Studies Support Causal Machine Learning Based Identification of Novel Drug Targets for High-Risk Multiple Myeloma (2018) (2)
Analysis of the effect of body weight on the efficacy and safety of epoetin alfa (2005) (2)
Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study (2020) (2)
The chemokine CXCL9 (MIG) is an independent predictor of overall survival in newly diagnosed multiple myeloma (2015) (2)
Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma (2021) (2)
Treatment outcome in AML: a single-centre experience in an unselected patient cohort (2012) (2)
Prevalence and incidence of anemia and risk factors for anemia in patients with cancer (2008) (2)
5-Fluorouracil and Folinic Acid with or without Alpha-2c Interferon in the Treatment of Metastatic Colorectal Cancer: Preliminary Results of a Multicenter Prospective Randomized Phase-Ill Trial (1995) (2)
Novel therapeutic agents for the management of multiple myeloma patients with renal impairment (2012) (2)
Supportive care. (2007) (2)
Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM) (2012) (2)
Flow Cytometric Evaluation of Traditional and Novel Surface Markers for the Diagnosis of Plasma Cell Dyscrasias (2019) (2)
Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma. (2022) (2)
Superior Efficacy of Carfilzomib and Dexamethasone (Kd56) Vs Bortezomib and Dexamethasone (Vd) in Multiple Myeloma (MM) Patients with Moderate or Serious Renal Failure: A Subgroup Analysis of the Phase 3 Endeavor Study (2017) (2)
Biosimilar Filgrastim Initiation in Patients Enrolled in the Monitor G-CSF Observational Study Relative to EORTC Guidelines (2012) (2)
Should alpha-interferon be included as standard treatment in multiple myeloma? Pro, Contra, Arbiter (1998) (2)
Maternal Embryonic Leucine Zipper Kinase (MELK) Drives a High-Risk Gene Network and Represents an Attractive Novel Drug Target in Multiple Myeloma (2016) (2)
Myeloma research on the move (2021) (2)
Pathogenesis and Treatment of Anemia (2004) (2)
Other Complications of Multiple Myeloma (2018) (2)
Pharmacovigilance in practice: erythropoiesis-stimulating agents (2014) (2)
Doxorubicin and paclitaxel improve survival compared with fluorouracil, doxorubicin and cyclophosphamide for women with metastatic breast cancer (2001) (2)
Prospective, Randomized Comparison between Double Transplantation (T) with Melphalan (200 mg/m2) and Triple T with Intermediate Dose Melphalan (100 mg/m2) in Patients with Multiple Myeloma (An Interim Analysis). (2006) (2)
Comparison of Proteasome Inhibition Activity between Carfilzomib and Bortezomib in the Phase 3 Endeavor Study (2017) (2)
Interferons in the treatment of multiple myeloma. (1990) (2)
Coxsackie B4 viral infection, anti-islet immunity and immunogenetics in insulin-dependent diabetes mellitus (1978) (2)
In vitro inhibitory effect of interferon on colony formation of myeloma stem cells (1980) (2)
Preclinical Evaluation of the First in Class BMI1 Inhibitor PTC-028 Confirms Potent Efficacy to Target BMI1-Addiction in Multiple Myeloma (2017) (2)
Beneficial effect of high-dose chemotherapy in multiple myeloma patients with unfavorable prognostic features. (2003) (2)
Supporting Patients with Cancer after Dobbs v. Jackson Women’s Health Organization (2022) (2)
Overall Survival of Relapsed/Refractory Multiple Myeloma Patients Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone: Results from the Phase 3 Endeavor Study According to Age Subgroup (2017) (2)
Pirarubicin (4′-o-tetrahydropyranil-adriamycin) for treatment of advanced breast cancer (1990) (2)
Prevention of infections including vaccination strategies in multiple myeloma (2022) (2)
Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma (2021) (2)
Hyperreactive cellular immunity in multiple myeloma [letter; comment] (1992) (2)
Vemurafenib Inhibits Myeloma Cell Growth Independent Of BRAF V600E Mutations, Potentiates The Activity Of Established Anti-Myeloma Drugs, but impairs Osteogenesis Via An HGF Autocrine Loop In Bone Marrow Stromal Cells (2013) (2)
Insulin Like Growth Factor Binding Protein 7 (IGFBP7) Is Downregulated in Multiple Myeloma with Consequneces for Myeloma Cell Growth and Bone Disease (2012) (1)
Use of Erythropoiesis-stimulating Agents (ESAs) in Lung Cancer Patients: Study-level and Patient-level Meta-analyses of Safety Outcomes (2010) (1)
New drugs on the horizon. Treatment of myeloma in 2020, a perspective (2015) (1)
Tailoring treatment in myeloma: are there clues from biology? (2015) (1)
of the International Myeloma Workshop Consensus Panel 3 Consensus recommendations for standard investigative workup: report (2012) (1)
[Lymphocyte subpopulations in multiple myeloma. Shift in the helper/suppressor cell relation]. (1982) (1)
Safety and efficacy of once-weekly carfilzomib (K) dosing in frail patients (pts): a subgroup analysis from the phase 3 A.R.R.O.W. study (2019) (1)
In reply [8] (2006) (1)
[Chemotherapy of advanced pancreatic cancer with 5-fluorouracil, doxorubicin and high-dose methotrexate]. (1988) (1)
[Scintigraphy using 111-indium-oxine-sulfate-labeled autologous granulocytes compared to scintigraphy using 99-Tc-pyrophosphate in inflammations of the jaw region]. (1984) (1)
ESAs not the culprit : More studies required. Authors' reply (2008) (1)
Maintenance with Interferon Alpha in Myeloma (1998) (1)
[Interferon (IFN) therapy (recombinant IFN-alpha-2C or recombinant IFN-gamma) in metastasized hypernephroma]. (1985) (1)
[Treatment of metastasizing breast cancer with aminoglutethimide]. (1982) (1)
Modeling of treatment response to erythropoiesis-stimulating agents in older (age≥70years) and younger (age<70years) patients with cancer and anemia: findings from the Anemia Cancer Treatment study. (2013) (1)
Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391). (2016) (1)
Patient‐reported pain severity and health‐related quality of life in patients with multiple myeloma in real world clinical practice (2021) (1)
[Interferon therapy in multiple myeloma]. (1988) (1)
Highlights of ASH 2019—multiple myeloma (2020) (1)
Reply to G. Ferretti et al (2009) (1)
Patient with high-grade fever, night sweats, and hepatosplenomegaly. (2011) (1)
Thalidomide-Interferon Vs. Interferon Maintenance Therapy After Thal-Dex Vs. MP Induction Therapy in Elderly Patients with Multiple Myeloma. (2009) (1)
Poorer Survival in Multiple Myeloma Correlates with Patients’ Age and Is Linked to a Higher Stage at Presentation but Prognostic Parameters Reflecting the Biology of the Myeloma Clone Are Not Associated with Age. (2004) (1)
Abnormal Serum IgA Kappa / IgA Lambda Ratios at Maximum Response Predict Poor Progression Free Survival in Myeloma Patients. (2009) (1)
Hyperreactive cellular immunity in multiple myeloma. (1992) (1)
Consolidation Treatment with VRD Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Trial of the European Myeloma Network (EMN02/HO95) (2020) (1)
Experimental treatment of chronic lymphocytic leukemia with extracorporeal photochemotherapy (1990) (1)
Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 Endeavor Study (NCT01568866) (2015) (1)
A Survey among Oncologists on Measures Needed to Improve Cancer Care (2007) (1)
Proceedings of an educational symposium at the 34th Annual Meeting of the European Group for Blood and Marrow Transplantation 30 March 2008 Florence, Italy Lenalidomide in multiple myeloma: in pursuit of optimal treatment (2008) (1)
[Surface morphology of leukemic B-lymphocytes]. (1976) (1)
Is bortezomib active in patients with mantle cell lymphoma? (2007) (1)
Double Transplantation with Melphalan (200 mg/m2) Compared with Triple Transplantation with Intermediate Dose Melphalan (100 mg/m2) in Patients with Multiple Myeloma (2008) (1)
Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma (2016) (1)
Imexon (AOP 99.0001) for Treatment of Relapsed or Refractory Multiple Myeloma: A Phase I/II Study (2008) (1)
Die Interferontherapie beim multiplen Myelom (1988) (1)
The Chromosomal Pattern 14q-Translocation Plus 13q-Deletion Is Characteristic for Multiple Myeloma after a Preceding Monoclonal Gammopathy of Undetermined Significance. (2004) (1)
Erythropoietin for chronic anemia of cancer: Treatment results and prediction of responsiveness (1995) (1)
Anaemia and cancer: oral or intravenous iron? (2012) (1)
512PChemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in solid tumours versus haematological malignancies: Patterns, outcomes and determinants (MONITOR-GCSF study) (2017) (1)
The development of a prediction tool for chemotherapy-induced anemia in patients with advanced non-small cell lung cancer (NSCLC) palliative receiving chemotherapy. (2006) (1)
Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study (2019) (1)
Epoetin alfa: future directions and future research. (2004) (1)
Lenalidomide and Dexamethasone for Acute Light Chain-Induced Renal Failure: Final Results of a Phase II Study (2014) (1)
Is there progress in the treatment of high-risk myeloma? (2017) (1)
Ixazomib in Combination With Thalidomide and Dexamethasone as Treatment for Patients With Relapsed/Refractory Multiple Myeloma: An Ongoing Phase II Trial (2017) (1)
OAB-035: Minimally invasive profiling of tumor and immune cells to stratify risk in smoldering multiple myeloma (SMM): the iMMunocell study (2021) (1)
Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance (2017) (1)
Pirarubicin(4′-0-Tetrahydropyranil-Doxorubicin) for Treatment of Metastatic Breast Cancer (1989) (1)
Intact Immunoglobulin or Fragments Thereof Can Be Detected in Urine in a Proportion of Patients with Multiple Myeloma and Are Associated with Reduced Survival At Presentation (2012) (1)
Superior Health-Related Quality of Life with Carfilzomib, Lenalidomide, and Dexamethasone versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma (MM): Results From the ASPIRE Trial (2015) (1)
Buchrezension (2017) (1)
Contents 18, No. 2, 1995 (1995) (1)
Fred Kubli (2007) (1)
Erratum to: Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study) (2016) (0)
myeloma well-tolerated regimen in patients with relapsed or refractory multiple Bendamustine-bortezomib-dexamethasone is an active and (2014) (0)
Chronic lymphocytic leukaemia – emerging treatment options: a report from the ASH Meeting 2009 (2010) (0)
PS1379 SAFETY AND EFFICACY OF ONCE-WEEKLY CARFILZOMIB DOSING IN FRAIL PATIENTS: A SUBGROUP ANALYSIS FROM THE PHASE 3 A.R.R.O.W. STUDY (2019) (0)
Incapacity due to cancer and cancer therapy (2009) (0)
University of Southern Denmark Diagnosis , treatment , and response assessment in solitary plasmacytoma updated recommendations from a European Expert (2018) (0)
bortezomib- containing regimens cell collection following initial therapy with thalidomide, lenalidomide or Mobilization in myeloma revisited: IMWG consensus perspectives on stem (2009) (0)
Contents Vol. 80, 2011 (2011) (0)
Impact of Number of Previous Treatment Lines and Pre-Treatment with Bortezomib or Lenalidomide on Efficacy of Bortezomib-Bendamustine-Dexamethasone (BBD) in Patients with Relapsed/Refractory Multiple Myeloma (MM) (2012) (0)
[Disturbances in granulocyte chemotaxis in patients with multiple myeloma]. (1979) (0)
MM-146 Using Data Science to Characterize Patterns in Cardiovascular Clinical Data: Topological Analysis of Baseline Characteristics in Patients With Relapsed/Refractory Multiple Myeloma Enrolled in Carfilzomib Trials. (2022) (0)
Contents, Vol. 185, 1982 (1982) (0)
Remission Maintenance in Multiple Myeloma (2004) (0)
Targeting of BMI-1 by the small molecule inhibitor PTC-209 demonstrates potent anti-myeloma activity in vitro (2015) (0)
Comparison of the Management of Anemia in Patients with Solid Versus Hematological Malignancies Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study (2008) (0)
Risk Factors of Thromboembolic Events in Multiple Myeloma Treated with IMiDs-Based Therapy While on LMWH Prophylaxis, (2011) (0)
S122 THE FIRST-IN-CLASS, ORALLY AVAILABLE BMI-1 MODULATORS PTC-028 AND PTC596 DISPLAY POTENT ACTIVITY IN PRE-CLINICAL MODELS OF MULTIPLE MYELOMA (2019) (0)
[Aminoglutethimide therapy in advanced breast cancer]. (1985) (0)
A222 Survival and Years of Life Lost in Different Age Categories of Patients with Multiple Myeloma (2009) (0)
[Technic and clinical use of radioactive labelling of autologous granulocytes]. (1988) (0)
Contents, Vol. 29, Supplement 2, 1989 (1989) (0)
[Serum ferritin and beta-2-microglobulin in multiple myeloma]. (1982) (0)
Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial) (2022) (0)
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma (vol 76, pg 853, 2016) (2016) (0)
P-096: Tackling pyrimidine biosynthesis - CTP Synthase 1 is a novel target in the treatment of multiple myeloma (2021) (0)
Author reply: Lenalidomide for bortezomib-resistant multiple myeloma (2010) (0)
Predictive R ole o f I nterphase C ytogenetics f or S urvival o f Patients W ith M ultiple M yeloma (2000) (0)
Cross-Links of Collagen Undetermined Significance: Quantification by Urinary Pyridinium Bone Resorption in Multiple Myeloma and in Monoclonal Gammopathy of (2013) (0)
Maternal Embryonic Leucine Zipper Kinase (MELK) is a key player and an attractive novel target in proliferation-associated high risk multiple myeloma (2017) (0)
Patient Confidence and Information Preferences During the Treatment Decision-making Process: Results From a Large Multiple Myeloma Patient Survey Across 12 Countries in Europe and Israel. (2023) (0)
15 INVITED Open questions about biosimilars – pharmacovigilance, substitution, labelling, naming and economy (2007) (0)
elderly patients with multiple myeloma Thalidomide-dexamethasone compared with melphalan-prednisolone in (2009) (0)
Syddansk Universitet Diagnosis , treatment , and response assessment in solitary plasmacytoma updated recommendations from a European Expert (2018) (0)
Supportive Therapie (2004) (0)
Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma (2019) (0)
Response to the publication: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. (2005) (0)
[The treatment of multiple myeloma]. (1994) (0)
ARE SERUM INTERLEUKIN-6 LEVELS ALWAYS USEFUL FOR DIFFERENTIATING MONOCLONAL GAMMOPATHIES IN UNSELECTED PATIENTS ?. AUTHOR'S REPLIES (1992) (0)
Evaluating the Safety of Erythropoiesis-Stimulating Agents (ESAs) in Patients with Breast Cancer, Lung Cancer, and Hematologic Malignancies: A Meta-Analysis of Randomized, Controlled Trials. (2007) (0)
A new prognostic model (MPI) for patients with myelofibrosis. (2004) (0)
The Management of Non-Hodgkin’s Lymphomas in Europe (1990) (0)
Thalidomide-interferon vs. interferon maintenance therapy afterinduction with Thal-Dex or MP in elderly patients with multiplemyeloma (2009) (0)
expression of myeloid membrane determinants 5q- chromosome in acute leukemia with lymphoid morphology and (2011) (0)
Anemia in cancer (2015) (0)
PS1509 QUALITY OF LIFE IN PATIENTS WITH RRMM DURING IXA-THAL-DEX INDUCTION AND IXAZOMIB MAINTENANCE THERAPY IN COMPARISON TO THE GENERAL POPULATION (2019) (0)
Contents, Vol. 30, 1990 (1990) (0)
Continuous treatment with lenalidomide in multiple myeloma: a case report (2012) (0)
High Prevalence of Iron Deficiency In Anemic and Non Anemic Patients with Various Types of Cancer (2010) (0)
Reply to Cavill's Letter to the Editor (2003) (0)
S179: RANDOMIZED COMPARISON BETWEEN KRD AND KTD INDUCTION, FOLLOWED BY K MAINTENANCE OR OBSERVATION IN TRANSPLANT NON-ELIGIBLE PATIENTS WITH NDMM (AGMT-MM02 TRIAL) (2022) (0)
Immunohistochemical Expression of Epidermal Growth Factor Receptor in Human Gliomas (1992) (0)
Multiple myeloma and primary hyperparathyroidism (1985) (0)
E ﬃ cacy and safety of car ﬁ lzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma (2020) (0)
Long-Term Treatment with Alpha-Interferon of Excessive Thrombocytosis in Myeloproliferative Disorders (1993) (0)
Intensification therapy with autologous stem cell transplantation versus bortezomib-melphalan-prednisone for newly diagnosed multiple myeloma patients: A multicenter, phase III study of the european myeloma network (EMN02/HO95 MM trial) (2017) (0)
Abstracts of the Annual Meeting of the Swiss Society for Oncology, Basel, March 1983 (2004) (0)
Heavy Chain/Light Chain Immunoassays for Monitoring Oligosecretory Multiple Myeloma Patients (2015) (0)
[Rethinking in oncology. More quality of life for patients by information? (interview by Christine Vetter)]. (2002) (0)
Early treatment for high-risk smouldering myeloma: has the time come? (2016) (0)
Maternal Embryonic Leucine Zipper Kinase (MELK): a Novel Marker of Poor Prognosis and Attractive Drug Target in High-Risk Patients with Multiple Myeloma (2015) (0)
Development, Prediction, and Treatment of Anemia in Patients (pts) with Lymphoma/Multiple Myeloma (L/M): Findings of Two European Surveys (ECAS and BEPOS). (2004) (0)
Contents, Vol. 23, Supplementum 3, 1983 (1983) (0)
Immunoglobulin-Like Transcript 2 (ILT2) Is Not Differentially Expressed in MGUS and Myeloma, but Appears To Be Downregulated at an Earlier Stage of Plasma Cell Disease. (2006) (0)
1596 Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia (CIN/FN) prophylaxis with biosimilar filgrastim and development of an outcomes risk calculator (MONITOR-GCSF study) (2015) (0)
Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma (2021) (0)
Cytogenetic abnormalities in myelofibrosis determined by FISH. (2004) (0)
Letrozol (Femara), novyi ingibitor aromatazy dlia lecheniia bol'nykh rasprostranennym rakom molochnoi zhelezy. (1999) (0)
Heavy/Light Chain assays identify monoclonal intact immunoglobulin in ‘Light Chain only’ patients (2015) (0)
5q - marker chromosome in acute leukemia with lymphoid morphology and myeloid differentiation antigens. (1985) (0)
An exploratory analysis of transfusion risk when initiating darbepoetin alfa (DA) therapy at baseline hemoglobin (Hb) = 10 g/dl in patients (pts) with chemotherapy-induced anemia (CIA). (2010) (0)
[New aspects in the clinical course determination and therapy in multiple myeloma]. (1979) (0)
Correction to: MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents (2021) (0)
High IKAROS Expression in Bone Marrow Environmental, But Not in Myeloma Cells Predicts for Survival with Lenalidomide-Dexamethasone Therapy in Myeloma (2017) (0)
Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study) (2021) (0)
P-143: SLIM CRAB criteria revisited: a meta-analysis of studies on 'biomarker defined early multiple myeloma’ (2022) (0)
Time to deterioration (TTD) in health-related quality of life (HRQoL) with carfilzomib plus dexamethasone (Kd56) versus bortezomib plus dexamethasone (Vd) in the ENDEAVOR trial. (2018) (0)
Response vs. nonresponse to treatment with erythropoiesis stimulating agents among breast cancer patients with anemia: findings from the European anemia cancer treatment study. (2009) (0)
P-104: Multi-omics data integration reveals molecular targets of carfilzomib resistance in multiple myeloma (2022) (0)
Management of Anemia in Multiple Myeloma Patients Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study (2008) (0)
Multiple Myeloma (MM) in Young Patients (pts): Clinical Features and Outcome in 259 Patients Younger Than 40 Years in Comparison to 8,296 pts Aged ≥ 40 Years. (2005) (0)
Late vs Early Response and Depth of Response Are Associated with Improved Outcomes: Post-hoc Analysis of Phase 3 TOURMALINE-MM1 Trial (NCT01564537) in Relapsed/Refractory Multiple Myeloma (RRMM) (2017) (0)
HL-A ANTIGENS AND CŒLIAC DISEASE (1974) (0)
Treatment Strategies in Multiple Myeloma: Biotherapy with Interferons (1997) (0)
[Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer]. (1999) (0)
CAR T cells in multiple myeloma: Where we stand and where we might be going (2022) (0)
947 Chemotherapy-associated anemia in breast cancer patients: prevalance and incidence from the European Cancer Anemia Survey (ECAS) (2003) (0)
Management of Anemia in Patients with Hematological Malignancies Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study (2008) (0)
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN). (2023) (0)
Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis. (2009) (0)
Overall Survival of Patients Post‐Transplant: Study Results from Two Phase 3 Trials ASPIRE and ENDEAVOR: MM‐107 (2018) (0)
Bortezomib-Based Transplantation and Consolidation Therapy Followed by Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma (2020) (0)
522PProof-of-concept of a risk calculator of chemotherapy induced (febrile) neutropenia (CIN/FN) based on real-world evidence (Monitor-GCSF study) (2017) (0)
CXCR3 Binding Chemokines MIG, IP-10 and ITAC Are Predictors of Overall Survival in Newly Diagnosed Multiple Myeloma (2014) (0)
SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of ‘biomarker-defined early multiple myeloma’—a systematic review with meta-analysis (2023) (0)
17 INVITED G-CSF biosimilars – approval process, substitution and extrapolation (2007) (0)
[Prognostic value of the degree of morphologic differentiation in multiple myeloma]. (1983) (0)
Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study) (2020) (0)
ESMO committed to improving cancer education. (2003) (0)
Cytostatic Anticancer Drug Development: Preclinical Studies and Early Clinical Trials (1990) (0)
Author's reply (0)
An exploratory analysis of transfusion risk when initiating darbepoetin alfa (DA) therapy at baseline hemoglobin (Hb) < 9 g/dl vs 9 to < 10 g/dl versus ≥ 10 g/dl in patients (pts) with chemotherapy-induced anemia (CIA). (2010) (0)
Longer Time to Best Response and Depth of Response Are Associated with Improved Duration of Best Achieved Response and Progression-Free Survival (PFS): Post-Hoc Analysis of Phase 3 Tourmaline-MM1 Trial in Relapsed/Refractory Multiple Myeloma (RRMM) (2016) (0)
Monokine Induced by Interferon-γ (MIG) Serum Levels Are a Marker of Disease Load and Correlate with Prognosis in Multiple Myeloma. (2006) (0)
Significance of morphological differentiation in the prognosis of multiple myeloma (1984) (0)
About the scientific programme (1996) (0)
B516 NT-proBNP Levels in Myeloma Patients Without Evidence of Amyloidosis (2009) (0)
High Expression of MUM1/IRF4 mRNA Is Associated with a Shorter Overall Survival in Patients with Multiple Myeloma. (2005) (0)
Both Hematologic and Renal Response Affect Overall Survival of Myeloma Patients with Acute Kidney Injury (2011) (0)
Short title: Thalidomide-Dexamethasone versus MP in myeloma (2008) (0)
The first-in-class BMI-1 modulators PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma (2019) (0)
myelofibrosis with myeloid metaplasia Chromosome 7 deletions are associated with unfavorable prognosis in (2011) (0)
Results of a new combination chemotherapy (etoposid-ifosphamide-mitoxantrone) in advanced NHL (1986) (0)
SLiM CRAB Criteria Revisited: Progression Patterns in Patients with Smoldering Multiple Myeloma Matching the Criteria of ‘Biomarker-Defined Early Multiple Myeloma’ - A Systematic Review with Meta-Analysis (2022) (0)
Haematologica August 2021 (2021) (0)
Rapid Reduction of Light-Chains and Proteinuria in Multiple Myeloma (MM) Patients with Light Chain Induced Acute Renal Failure Treated with Lenalidomide and Dexamethasone (2011) (0)
Significant Activity of Lenalidomide-Dexamethasone in Multiple Myeloma (MM) Patients with Light Chain Induced Acute Renal Failure (LC-ARF) (2012) (0)
PF564 OUTCOMES OF PATIENTS WITH T(11;14) MULTIPLE MYELOMA: AN INTERNATIONAL MYELOMA WORKING GROUP MULTICENTER STUDY (2019) (0)
Update of clinical highlights presented at the 2017 American Society of Hematology Meeting (2018) (0)
Contents, Vol. 5, 1897 (0)
Contents, Vol. 42, Supplement 1, 1985 (1985) (0)
Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment (2017) (0)
Contents, Vol. 20, Supplement 2, 1980 (1980) (0)
Ixazomib in Combination with Thalidomide and Dexamethasone for Induction and Ixazomib Maintenance Therapy Overcomes High-Risk Cytogenetics (but not of 1q21 Gain) in Relapsed/Refractory Multiple Myeloma — AGMT_MM1 (2018) (0)
Contents Vol. 70, 2006 (2007) (0)
Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop. (2023) (0)
Indoleamine 2,3-dioxygenase (IDO) may not be a major factor for tumor immune evasion in multiple myeloma (2007) (0)
A146 Management of Anemia in Multiple Myeloma Patients with Anemia: Findings from the A.C.T. Study (2009) (0)
[Erythropoiesis stimulating proteins for the treatment of anemia in cancer patients]. (2010) (0)
autologous stem cell transplantation treatment of multiple myeloma patients who are candidates for International Myeloma Working Group consensus approach to the (2012) (0)
CTP Synthase 1 Is a Novel Therapeutic Target in Lymphoma (2023) (0)
Contents, Vol. 96, 1976 (1976) (0)
OCEAN (OP-103): Melflufen/Dexamethasone Compared Wth Pomalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - Subgroup Analysis in Patients Refractory to Prior Alkylators (2022) (0)
A new prognostic model (MPI) for patients with myelofibrosis (2004) (0)
A reply to Efficaces’ letter to the editor (2009) (0)
Results of autologous transplantation for multiple myeloma (MM) in Austria. An analysis based on data from the Austrian Stem Cell Transplantation (ASCT) Registry. (2004) (0)
Abstract P5-15-19: Prophylaxis of chemotherapy-induced febrile neutropenia with biosimilar filgrastim: Description of patients, treatment patterns and outcomes in the MONITOR-GCSF study in the breast cancer cohort (2015) (0)
transformation from MGUS to multiple myeloma Patterns of somatic mutations in VH genes reveal pathways of clonal (2013) (0)
B545 Tracking the Stem Cell in Light Chain Myeloma (2009) (0)
[Determination of the tumor cell mass and its significance as a parameter for prognosis and therapy in patients with multiple myeloma]. (1978) (0)
Subject Index Vol. 70, 2006 (2007) (0)
Favorable Survival of Multiple Myeloma Patients with t(11;14)(q13;q32) Plus Normal Chromosome 13q. (2004) (0)
Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial) (2020) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Heinz Ludwig?

Heinz Ludwig is affiliated with the following schools:

Heinz Ludwig's Academic­Influence.com Rankings

Why Is Heinz Ludwig Influential?

Heinz Ludwig's Published Works

Published Works

What Schools Are Affiliated With Heinz Ludwig?

Heinz Ludwig's AcademicInfluence.com Rankings